Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.27 +0.16 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,608,800
Open 46.14
Bid (Size) 46.00 (2)
Ask (Size) 46.27 (1)
Prev. Close 46.11
Today's Range 46.09 - 46.29
52wk Range 28.21 - 62.00
Shares Outstanding 49,127,913
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+28.2%
+28.2%
1 Month
+24.9%
+24.9%
3 Month
-17.8%
-17.8%
6 Month
+33.9%
+33.9%
1 Year
+9.0%
+9.0%

More News

Read More
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
From Kahn Swick & Foti, LLC
Via Business Wire
Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Analyst Expectations For SpringWorks Therapeutics's Future
Via Benzinga
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Via Benzinga
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
Via Stocktwits
No Quick Fix For This Market
Via Talk Markets
Topics Stocks / Equities
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
Via Stocktwits
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Top 3 Health Care Stocks You May Want To Dump In February
Via Benzinga
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
Via Stocktwits
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug
Via Benzinga
Exposures Product Safety
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is SpringWorks Therapeutics, Inc. - common stock publicly traded?
Yes, SpringWorks Therapeutics, Inc. - common stock is publicly traded.
What exchange does SpringWorks Therapeutics, Inc. - common stock trade on?
SpringWorks Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for SpringWorks Therapeutics, Inc. - common stock?
The ticker symbol for SpringWorks Therapeutics, Inc. - common stock is SWTX on the Nasdaq Stock Market
What is the current price of SpringWorks Therapeutics, Inc. - common stock?
The current price of SpringWorks Therapeutics, Inc. - common stock is 46.27
When was SpringWorks Therapeutics, Inc. - common stock last traded?
The last trade of SpringWorks Therapeutics, Inc. - common stock was at 05/19/25 04:00 PM ET
What is the market capitalization of SpringWorks Therapeutics, Inc. - common stock?
The market capitalization of SpringWorks Therapeutics, Inc. - common stock is 2.27B
How many shares of SpringWorks Therapeutics, Inc. - common stock are outstanding?
SpringWorks Therapeutics, Inc. - common stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.